Sign in Subscribe
Vaccines

The Science Behind the HPV Vaccine: Why It's Given to Teenagers

Strategic Insights

— 2 min read

The human papillomavirus (HPV) is a leading cause of cancer deaths among women worldwide, and the HPV vaccine can prevent up to 90% of cervical cancers. However, some parents question why the vaccine is predominantly offered to girls in their early teens rather than being offered to everyone later on. The answer lies in the science behind the vaccine's safety and effectiveness, which reveals that the vaccine works best when given early, building long-lasting protection against cancers caused by HPV.

Key Takeaways:

  • The HPV vaccine is most effective when given to girls aged 9-14 years, as it offers the highest biological and public health benefit.
  • Immunological studies suggest that younger adolescents mount a stronger response to the HPV vaccine compared to older age groups.
  • Vaccinating girls in this age group also reduces the risk of HPV infection in boys.
  • Modelling evidence from low- and middle-income countries suggests that targeting HPV vaccination to girls aged 15-20 years is significantly more efficient than vaccinating boys or older girls.
  • The World Health Organization recommends prioritizing HPV vaccination in girls aged 9 to 14 years, noting that doing so also reduces the risk of HPV infection in boys.
  • More than 200 million doses of HPV vaccine have been given globally since its introduction, with its safety continuing to be tracked through national and international monitoring systems.
  • A systematic review and meta-analysis found no significant differences in serious adverse events, gastrointestinal or skin reactions, headaches, or fever between people who received HPV vaccines or a placebo.
  • People who received the HPV vaccine experienced some local reactions, such as injection site pain, swelling, and redness, but these responses are not dangerous and are a sign that the immune system is responding to vaccination.
  • Research by the Vaccine Impact Modelling Consortium has estimated that for every 1,000 children vaccinated against HPV, an estimated 17.4 deaths are prevented.

Statistics:

  • 90% of cervical cancers can be prevented by the HPV vaccine (Source: [No source explicitly stated in the original text])
  • The HPV vaccine is most effective when given to girls aged 9-14 years, with a 90% reduction in cervical cancer cases (Source: [No source explicitly stated in the original text])
  • More than 200 million doses of HPV vaccine have been given globally since its introduction (Source: The global distribution of HPV vaccine)
  • Research estimates that for every 1,000 children vaccinated against HPV, an estimated 17.4 deaths are prevented (Source: Vaccine Impact Modelling Consortium)
  • In the US, there was a 62% drop in cervical cancer deaths over the past decade, with HPV vaccination considered the most likely explanation (Source: Researchers in the US)

Sources:

  • The global distribution of HPV vaccine
  • World Health Organization's (WHO's) latest position paper on HPV vaccines
  • Systematic review and meta-analysis of HPV vaccine safety published in 2025 (no specific source title mentioned)
  • Research by the Vaccine Impact Modelling Consortium
  • Study published in Eurosurveillance in July 2025 (no specific source title mentioned)
  • Researchers in the US

Read more